Virica pioneered a new product category of Viral Sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. Customized VSE formulations optimize research processes and enhance production. VSEs are small molecules that reduce the anti-viral responses of cells, thereby improving product yields and therapeutic efficacy for gene therapies, vaccines and oncolytic viruses. Virica's business model includes developing and supplying VSEs as manufacturing reagents and formulating VSEs to build better therapies. Virica’s leadership team is experienced in building and operating hyper-growth companies. Virica is raising a Series A round of US$5 million, in order to build on the traction to date and allow the platform to reach its full potential.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
VSE molecules for manufacturing and therapeutics
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):